---
title: Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
date: '2024-05-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38767614/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240520180847&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In patients with COPD and type 2 inflammation as indicated
  by elevated blood eosinophil counts, dupilumab was associated with fewer exacerbations
  and better lung function than placebo. (Funded by Sanofi and Regeneron Pharmaceuticals;
  NOTUS ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: In patients with COPD and type 2 inflammation as indicated by elevated blood eosinophil counts, dupilumab was associated with fewer exacerbations and better lung function than placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; NOTUS ClinicalTrials.gov number, ...